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Discovery of Hepatitis C Virus: 




Scientists were successful in discovering Hepatitis A and B, but there is another 
virus which has a long incubation period, many people are asymptomatic and cause 
adverse effects. Three scientists Harvey J Alter, Michael Houghton and Charles M 
Rice who have contributed their work in discovering a non-A, non-B hepatitis virus 
called Hepatitis C. Hepatitis is a disorder associated with the functioning hepatic 
cells in the liver. The person infected with Hepatitis C will have poor functioning of 
liver, vomiting, fatigue, jaundice and appetite. In this paper, I am going to explain 
about the Hepatitis C virus, and the work was done by three scientists and various 
research around it.
Keywords: Hepatitis C, Post-transfusion, non-A non-B hepatitis, Gene expression, 
Antigen antibody reaction
1. Introduction
Hepatitis C virus is a blood-borne pathogen. The person infected with this virus 
has defects in the functioning of the liver and blood. The progress of the virus in the 
human body is slow acting. The incubation period varies from person to person, it is 
about 2–3 months [1]. Hepatitis C is associated with chronic hepatitis which means 
inflammation of the liver and may also lead to liver failure sometimes cancer called 
Hepatocellular carcinoma [2]. According to the World Health Organization, it was 
estimated that there are about 70 million of the total world population infected with 
the Hepatitis C virus [3, 4]. If the treatment is delayed, the disease will progress and 
cause liver cirrhosis and hepatocellular carcinoma [5]. Hepatitis C is causing 400 
000 deaths annually [4].
2. Discovery of hepatitis A and B
In 400 B.C., Hippocrates called hepatitis infection as ‘Epidemic Jaundice’ and 
told that “The bile contained in the liver is full of phlegm and blood, and erupts..
Such an eruption, the patient soon raves, becomes angry, talks nonsense and barks 
like a dog” [6]. During the second world war, the infection to the liver was thought 
of infection by several viruses and called it ‘Viral Hepatitis’. After that, in 1947, 
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British hepatologist F.O. MacCallum has classified viral hepatitis into Hepatitis A 
which is Epidemic hepatitis and Hepatitis B which is serum hepatitis [7].
Baruch Blumberg (1925–2011) was a geneticist at National Institute of Health 
in Bethesda who is working on human disease susceptibility. He collected blood 
samples of people from many places in the world to study inherited diseases and 
susceptibility [7]. He found an unfamiliar reaction taking place in the serum of a 
hemophilic patient who needs blood and an Australian aborigine who is a donor. 
He initially thought that he discovered a new lipoprotein. After that, in the serum 
of a hemophilic patient, he could find detection of a new antigen, he called that 
as ‘Australian-antigen’ [7, 8]. In 1967, Blumberg linked the Australian-antigen 
with viral hepatitis, and in 1968, Alfred Price used Immuno-electrophoretic 
technique to explain that serum antigen that Blumberg discovered was related 
to hepatitis and called it as Serum hepatitis antigen. Later, both Australian-
antigen and Serum hepatitis antigen were confirmed that these are viral particles. 
Blumberg performed several serological tests using chimpanzees to confirm the 
antigens are of Hepatitis B virus. In 1976, Blumberg got Nobel Prize Physiology 
and Medicine [9]. At that time, it was impossible to identify who are carriers of 
diseases and who are healthy donors, the effect of disease on a person is silent and 
progressive [4].
3. Discovery of hepatitis C
3.1 Harvey J Alter
Along with Blumberg, there is another person who also contributed his work 
in discovering Hepatitis B is Harvey J Alter. Alter also worked at National Institute 
of Health in Bethesda [10]. In the 1970s, people started studying the relationship 
between blood donors infected with Hepatitis B and post-transfusion hepatitis [8]. 
While they were studying about this, Alter found out that, though Hepatitis B posi-
tive donors prevented from donating blood, he found that blood transfused people 
were still infected with other ‘Hepatitis related infections’ [11]. Alter came across 
a patient who had a mild form of the disease and later that patient had Hepatitis 
associated diseases after a long incubation period. Based on this, he proposed that 
there may be two different viruses causing ‘post-transfusion hepatitis’ [11]. In 1975, 
Feinstone, Purcell and other scientists tested patients who are non-B hepatitis and 
found that Hepatitis A is not causing the disorders [12, 13].
The blood transfusion of non-B hepatitis was spreading to more numbers of 
people. They were sure the infection was not because of Hepatitis A or B, then 
came up with a term called ‘non-A, non-B hepatitis’ (NANBH) [12, 13]. Alter 
and his colleagues were clear that NANBH is responsible for post-transfusion 
hepatitis, but they were unable to show what NANBH is? Since there is no tool 
to diagnose NANBH, many people got affected by blood transfusion. The only 
animal model which is susceptible to NANBH is chimpanzees, Tabor et al. [14] 
have infected chimpanzees to study the hepatocyte infection and agents causing 
the disease. They have taken plasma from NANBH people and infected chimpan-
zees, and they found cirrhosis and hepatocellular carcinoma disorders in animal 
[4]. After several experiments, Alter and his colleagues found that NANBH has 
essential lipids which are enveloped around the virus which are different from 
Hepatitis B [15, 16]. Alter did not give conclusive results to state the causative 
agent is causing post-transfusion hepatitis.
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3.2 Michael Houghton
In 1982, Houghton worked at Chiron Corporation and came up with molecular 
methods called cDNA library. Houghton and his colleagues infected chimpanzees with 
NANDH virus and have taken plasma from them, that plasma they have centrifuged to 
get a pellet of virus and they have extracted the nucleic acid from it. They have dena-
tured the nucleic acid because they do not know whether it is DNA or RNA. After 
denature, they synthesized the cDNA [17]. They transduced the cDNA to a bacterial 
vector using a bacteriophage λ gt11 strain, the method is called transduction [18]. The 
bacterial vector undergoes translation to display cDNA-encoded polypeptides. They 
also looked for whether similar antigen that is expressed in the serum of NANBH 
patients by using screening techniques. If an antigen is found in the body, the immune 
system will generate antibodies against it. They have considered those patients as 
sources of viral antibodies, they have taken plasma by centrifuging blood of NANBH 
patients [18]. The bacterial vector has expressed the cDNA proteins, and by introduc-
ing plasma of the patient to the bacterial colony, the antibodies in the plasma will bind 
to polypeptides of bacteria [4]. Based on this idea of Molecular Biology and 
Immunology, they performed several screenings of the above experiment about 610  
and found there is one colony that did not match human or chimpanzee DNA 
sequence, it matched with the sequence of a virus family called Flaviviridae [4]. They 
named it as cDNA clone 5–1-1 and named it as Hepatitis C virus (Figure 1) [17– 20].
Houghton and his colleagues have immediately taken this knowledge further. 
They have collected suspected blood samples from Alter and performed the above 
experiment on those samples. They found all the blood samples they have tested 
are positive Hepatitis C. Using this diagnostic technique, donors were tested blood 
samples before transfusion which decreased the number of hepatitis cases [4]. But, 
Houghton has not evidently proved that Hepatitis C is only the causative agent or a 
mix of viruses causing disorder?
3.3 Charles M Rice
To find out what is actually causing chronic liver cirrhosis, two scientists 
Kunitada Shimontohno and Charles Rice came up with a new experiment. Blight 
and Rice [21], they have sequenced the viral genome and found that it is positive 
RNA strand about 96000 nucleotides, the RNA undergoes direct translation to form 
proteins, the primary transcription process is eliminated. The viral genome is a long 
Figure 1. 
Summary of Houghton work.
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open reading frame (ORF), different types of proteins are translated from one ORF 
which has several translation initiation and termination codons [21].
They have found that there is a non-coding region at the 3’and 5′ ends of the viral 
RNA genome which is responsible for replication of the virus [21, 22]. Kolykhalov et 
al. [23] have constructed a viral genome which has conserved 3′ region at 5′ nontrans-
lated region (5’ NTR) and rest in long ORF (Figure 2). That genome gene they have 
injected to the chimpanzee liver to check the viral replication, but unfortunately the 
experiment failed, they did not find new viruses in the blood. While finding reasons 
for failure of experiment, they came across that during replication, mutations are 
common in the viral genome. To eliminate the mutations, they have engineered a 
few new sequences with silent markers. With all new sequences, they have created 
a new repaired conserved 3′ region (Figure 3) [4, 23, 24]. They repeated the above 
experiment with a newly engineered genome and the experiment worked resulting in 
chimpanzees having liver cirrhosis and hepatocellular carcinoma. Based on this, Rice 
gave the conclusion that only Hepatitis C virus alone causes hepatitis, there no other 
causative agent involved.
4. Mode of infection and diseases
Figure 3. 
Repaired conserved 3’ region Genomes [23].
Figure 2. 
Viral genome with conserved 3’ region.
Virus Type Family Genetic 
material
Disorders Disorders
Hepatitis A Picornaviridae RNA Contaminated food 
and water
Abdominal pain, nausea, 
fatigue
Hepatitis B Hepadna DNA Blood transfusion Liver failure, jaundice
Hepatitis C Flaviviridae RNA Blood transfusion Inflammation of liver and 
hepatocellular carcinoma
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5. Molecular mechanisms of replication
Structure of Virus: Hepatitis C is a single-stranded RNA virus belonging to 
the family of Flaviviridae and there are seven genotypes (gt 1–7) and 67 subtypes 
which states genetic diversity is high [5]. The size of the virus is about 56–65 nm in 
diameter and the viral core about 45 nm. In the viral envelope, there are viral spikes 
which are formed by E1 and E2 glycoprotein heterodimers. Viral membranes consist 
of several lipoproteins those are low-density lipoprotein (LDL), very-low-density 
lipoprotein (VLDL) and apolipoproteins (Apo) which are A1, B, C (Figure 4) [5].
Viral Genome: As described above, viral genomes contain 96000 nucleotides 
and one ORF with the coding region of 3010 to 3033 nucleotides and 5′ and 3′ ends 
have non-translational (NTR) regions. The translation of viral RNA takes place in 
the endoplasmic reticulum of hepatic cells in the liver which is initiated by the IRES 
region which is adjacent to 5’NTR (Figure 3). The translation results in the forma-
tion of three structural proteins which are core, E1 and E2 and seven non-structural 
proteins which are p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B. The structural proteins 
form viral components and non-structural proteins regulate viral growth and 
replication (Figure 5) [5].
Viral Cycle: When a person has blood transfusion from the Hepatitis C  
infected person, the virus reaches to the liver cell and binds to the lipoviral receptor 
proteins and the whole virus is engulfed into the cell by a process called clathrin-
mediated endocytosis. The virus reaches the endoplasmic reticulum and releases its 
RNA. The ORF of RNA is translated to form structural and non-structural proteins.  
Figure 4. 
Structure of hepatitis C .
Figure 5. 
Viral genome expression [5].
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As I mentioned, the structural proteins form viral components and non-structural 
proteins regulate viral growth and replication using cellular components. The viral 
components and replicated RNA fragments reach the Golgi apparatus and unite to 
form mature viruses. The formed viruses enter the blood by bursting the liver cell. 
One single entry produces millions of viruses that cause liver dysfunction by bursting 
hepatic cells [5].
6. Research: a way to discovery of vaccine
Phosphatidylinositol 4-kinase IIIα (PI4KA) is a hepatic cellular protein which 
converts phosphatidylinositol to phosphatidylinositol 4-phosphate (PI4P) [25]. This 
protein has several roles in the viral replication and growth in an infected cell. 
PI4KA interacts with structural proteins in shaping the virus and also interaction 
with the non-structural protein of NS5B will accumulate the essential cellular 
material for viral growth [26]. When the Phosphatidylinositol 4-kinase III?? is 
knocked down, the replication and production of viral components are affected. 
Harak et al. [26] have done an in-vitro gene knockdown method to inhibit viral 
growth. Sarhan et al. [27] have also done similar experiments. They found other 
proteins called GSK3α  and β  interacting with viral NS5A. The GSK3α  and β  
phosphorylates the NS5A. The phosphorylation of NS5A results in multiple func-
tions such as viral maturation and release. If the GSK3α  and β  genes are knocked 
down, the viral maturation and release is inhibited [27].
When any foreign particles enter the body, our immune system will identify 
that antigen. The human immune system has B cells, T cells and Natural killer 
cells play essential roles in detecting antigens. Hepatitis C virus has E2 glycopro-
tein in the core. CD81 markers which are present on B-cells will interact with E2 
glycoprotein [28]. The binding of E2 and CD81, B-cells release serum antibodies to 
neutralize the viral activity. Research around Molecular Biology and Immunology 
will increase the chances of discovering the vaccine. Research is the stepping stone 
to discovering new things in science.
7. Diagnosis and treatment
When Hepatitis C is infected, the majority of the people are asymptomatic. The 
incubation period varies from person to person. In order to detect the virus, there 
are diagnostic tests to be performed. There are two ways to direct the virus, one is 
an indirect method based on antibodies production and direct method based on 
viral detection. In the indirect method, a person’s blood sample will be taken which 
consist of serum, blood and plasma. To that blood, recombinant viral proteins 
core, NS3 and NS4 antigen are added. Along with recombinant proteins, colloidal 
gold labeled protein A is added. If the antibodies bind to antigens, the recombinant 
protein generates reddish-purple lines. This screening test will reveal that antibod-
ies are present. To confirm the person infected with Hepatitis C, Recombinant 
Immunoblot Assay (RIBA) is antibody specific test which will direct anti-hepatitis 
C antibodies [29]. In the direct method diagnosis, Reverse-transcriptase polymerase 
chain reaction (RT-PCR) is performed which directly gives confirmatory results 
whether the virus is present or not [29].
The current work going on Hepatitis C is discovering a vaccine. To cure Hepatitis 
C, there is no vaccine. If the disorder is in advanced stages, the person needs liver 
transplantation. If Hepatitis C is directed at early stages like at chronic hepatitis 
stage, there are antiviral drug treatments which cure disorder to some extent. These 
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antiviral drugs interfere with viral replication and maturation [3]. There are several 
classes of drugs which interfere with viral growth. The nonstructural 3/4A inhibi-
tor drugs Boceprevir and telaprevir interfere with NS3/4 A proteins to inhibit the 
viral protein formation. Nonstructural 5A inhibitors like Ledipasvir, ombitasvir, 
daclatasvir etc., will interfere with NS5A protein which plays an important role in 
viral replication and assembly of viral particles. Nonstructural 5B inhibitors like 
sofosbuvir interfere with NS5B which synthesizes viral RNA [3]. Treating patients 
with antiviral drugs will inhibit viral progress in the body. These drug targets cure 
the disease if the disease is at an early stage.
8. Conclusion
Alter, Houghton, Rice and their colleagues have contributed their work to the 
world of science. They have come up with new molecular and immunological 
techniques to detect the presence of viruses. Alter and his colleagues discovered 
an Australian antigen and it was non-A, non-B hepatitis (NANBH). He introduced 
a model organism chimpanzees to study the disease post-transfusion hepatitis. 
Houghton and his colleagues have brought Molecular Biology and Immunology 
together and diagnosed NANBH and named it as Hepatitis C virus. Rice and his 
colleagues sequenced the viral genome and explained its properties of replication 
and gene expression. He discovered that alone Hepatitis C is causing Liver cirrhosis 
and Hepatocellular carcinoma.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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